Jorge J Castillo: Influence Statistics

Jorge J Castillo

Jorge J Castillo

Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. | Bing Center for Waldenström Macroglobulinemia, Dana-Farber ...

Jorge J Castillo: Expert Impact

Concepts for which Jorge J Castillo has direct influence: Waldenström macroglobulinemia , Patients wm , Mutated myd88 , Multiple myeloma , Latin america , Waldenström macroglobulinaemia , Wm patients .

Jorge J Castillo: KOL impact

Concepts related to the work of other authors for which for which Jorge J Castillo has influence: Cell lymphoma , Multiple myeloma , Waldenström macroglobulinemia , Diffuse large , Chronic lymphocytic leukemia , Barr virus , Bone marrow .

KOL Resume for Jorge J Castillo

Year
2022

Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Hematology, Dana Farber Cancer Institute, Boston, United States of America

Hematologic Oncology Treatment Center, Dana‐Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

2021

Harvard Medical School, Bing Center for Waldenstrom's Macroglobulinemia, Boston, USA

Bing Center for Waldenstrom's Macroglobulinemia.

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA

2020

Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

7Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.

Division of Hematologic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts

Department of Medicine, Harvard Medical School, Boston, MA

2019

Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

3 Harvard Medical School, Boston, MA.

Dana-Farber Cancer Institute, Boston, MA

2018

Bing Center for Waldenström's Macroglobulinemia Dana‐Farber Cancer Institute Boston Massachusetts

Department of Medical Oncology, Dana Farber Cancer Institute, and.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA;, http://orcid.org/0000-0001-9490-7532

Harvard Medical School, Boston, MA; and

Dana Farber Cancer Institute;

Prominent publications by Jorge J Castillo

KOL-Index: 18563 . Activating mutations in MYD88 are present in ∼95% of patients with Waldenström macroglobulinemia (WM), as well as other B-cell malignancies including activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL). In WM, mutated MYD88 triggers activation of Bruton tyrosine kinase (BTK). Ibrutinib, a pleiotropic kinase inhibitor that targets BTK, is highly active in patients with mutated ...
Known for Mutated Myd88 | Btk Ibrutinib | Activation Hck | Large Bcell
KOL-Index: 12895 . Approximately a third of the patients with diffuse large B-cell lymphoma present with extranodal involvement. Our study aims to identify primary extranodal sites of disease associated with prognosis in patients with diffuse large B-cell lymphoma (DLBCL) in the rituximab era. A secondary objective is to describe epidemiological and clinical characteristics of patients with extranodal DLBCL. ...
Known for Extranodal Involvement | Diffuse Large | Cell Lymphoma | Patients Dlbcl
KOL-Index: 12836 . BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory ...
Known for Ibrutinib Patients | 3 Trial | Refractory Waldenström | Treatment Disease
KOL-Index: 11790 . BACKGROUND: Medical oncologists often must deliver bad news. The authors were interested in the extent of formal training in delivering bad news in hematology/oncology fellowships in the United States. METHODS: An e-mail survey was sent to all hematology/oncology fellowship program directors in the United States. Surveys were e-mailed to 124 program directors and responses were received ...
Known for Program Directors | Formal Training | United States | Graduate Fellowships
KOL-Index: 11504 . Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease were randomly assigned 1:1 to treatment with ...
Known for Waldenström Macroglobulinemia | Randomized Phase | 3 Trial | Zanubrutinib Ibrutinib
KOL-Index: 11181 . Smoking has been postulated as an environmental risk factor for acute myeloid leukemia (AML). The primary objective of this meta-analysis of observational studies was to evaluate the epidemiologic relationship between smoking and the risk of development of AML. Twenty-three studies published between January 1993 and December 2013 were included in our analysis, and accounted for 7,746 cases ...
Known for Cigarette Smoking | Acute Myeloid Leukemia | Epidemiological Studies | Risk Aml
KOL-Index: 11179 . Next-generation sequencing has revealed recurring somatic mutations in Waldenström macroglobulinemia (WM). Commonly recurring mutations include MYD88 (95% to 97%), CXCR4 (30% to 40%), ARID1A (17%), and CD79B (8% to 15%). Diagnostic discrimination of WM from overlapping B-cell malignancies is aided by MYD88 mutation status. Transcription is affected by MYD88 and CXCR4 mutations and includes ...
Known for Waldenström Macroglobulinemia | Cxcr4 Mutations | Patients Wm | Mutated Myd88
KOL-Index: 10789 . BACKGROUND.: Prognostic factors and outcomes in patients with marginal zone lymphoma (MZL) have been studied in small cohort studies, which may not reflect the population at large. METHODS.: Clinical characteristics and survival outcomes of adult patients with MZL who were diagnosed between 1995 and 2009 were evaluated using the Surveillance, Epidemiology, and End Results (SEER) database. ...
Known for Patients Nmzl | Zone Lymphoma | Survival Outcomes | Bcell Mzl
KOL-Index: 10140 . Hyponatremia, a common electrolyte abnormality in oncology practice, may be a negative prognostic factor in cancer patients based on a systematic analysis of published studies. The largest body of evidence comes from small-cell lung cancer (SCLC), for which hyponatremia was identified as an independent risk factor for poor outcome in six of 13 studies. Hyponatremia in the cancer patient is ...
Known for Hyponatremia Siadh | Cancer Patient | Fluid Restriction | Arginine Vasopressin
KOL-Index: 10117 . MYD88 L265P is highly prevalent in Waldenstrom’s Macroglobulinemia (WM) and IgM monoclonal gammopathy of unknown significance (MGUS). We investigated whether MYD88 L265P could be identified by peripheral blood (PB) allele-specific PCR. MYD88 L265P was detected in untreated WM (114/118; 96.6%); previously treated WM (63/102; 61.8%); and IgM MGUS (5/12; 41.7%) but in none of 3 hyper-IgM or ...
Known for Myd88 L265p | Undetermined Significance | Peripheral Blood | Igm Monoclonal
KOL-Index: 10039 . Bortezomib frequently produces severe treatment-related peripheral neuropathy (PN) in Waldenström's macroglobulinemia (WM). Carfilzomib is a neuropathy-sparing proteasome inhibitor. We examined carfilzomib, rituximab, and dexamethasone (CaRD) in symptomatic WM patients naïve to bortezomib and rituximab. Protocol therapy consisted of intravenous carfilzomib, 20 mg/m2 (cycle 1) and 36 ...
Known for Carfilzomib Rituximab | Waldenströms Macroglobulinemia | 1 2 | Maintenance Therapy
KOL-Index: 9740 . BACKGROUND: Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear. PATIENTS AND METHODS: We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using ...
Known for Cell Lymphoma | Frontline Therapy | Multivariate Analysis | Ptcl Patients

Key People For Waldenström Macroglobulinemia

Top KOLs in the world
#1
Steven Peter Treon
waldenström macroglobulinemia consultancy funding patients wm
#2
Meletios‐Athanassios Dimopoulos
multiple myeloma consultancy honoraria board directors
#3
Robert A Kyle
multiple myeloma undetermined significance consultancy funding
#4
Morie Abraham A Gertz
multiple myeloma consultancy funding stem cell
#5
Zachary R Hunter
waldenström macroglobulinemia wm patients myd88 l265p
#6
Irene M Ghobrial
multiple myeloma board directors advisory committees

Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. | Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; | Hematology, Dana Far